Skip to main content

Table 3 On-going studies evaluating first-line therapies for metastatic urothelial cancer

From: Biomarkers for immunotherapy in bladder cancer: a moving target

Therapy Number Phase Primary Endpoint Trial ID Estimated Completion Date
Atezolizumab + Gemcitabine/Carboplatin vs. Gemcitabine/Carboplatin (IMvigor 130) 1200 III PFS/OS NCT02807636 July 2020
Pembrolizumab +/− Platinum vs Gemcitabine/Platinum (Keynote 361) 990 III PFS/OS NCT02853305 March 2020
Durvalumab +/− Tremelimumab vs. Gemcitabine/Carboplatin (1:1:1) 525 III PFS/OS NCT02516241 July 2019
Pembrolizumab + CVA21 (Coxsackievirus A21) 90 I Safety NCT02043665 August 2019
Nivolumab + NEO-PV-1 (personalized peptide vaccine) 90 Ib Safety NCT02897765 December 2020
Pembrolizumab + sEphB4-HSA 60 II OS NCT02717156 November 2020
Gemcitabine/Cisplatin +/− Ipilimumab (Active, not accruing) 36 II Safety/ORR NCT01524991 November 2017
Atezolizumab +/− Gemcitabine Cisplatin (First line metastatic or MIBC) 30 I/II Safety NCT02989584 December 2020